B7-H3 + CSPG4 co-targeting CAR-T cells

**B7-H3 + CSPG4 co-targeting CAR-T cells** is a research-stage, target-specific dual-CAR T-cell platform developed at the University of North Carolina for **triple-negative breast cancer**. Autologous T cells are engineered with CARs recognizing B7 homolog 3 protein and chondroitin sulfate proteoglycan 4, enabling cytotoxic recognition of tumor cells expressing either antigen and seeking to reduce relapse caused by heterogeneous antigen expression or antigen escape. In preclinical TNBC patient-derived xenograft models, optimized dual-specific CAR-T cells eradicated tumors with mixed B7-H3 and CSPG4 antigen expression. The published work evaluated dual-CAR configurations using CD28 or 4-1BB costimulatory endodomains in trans with a shared CD3ζ activation domain; the B7-H3 CAR cassette incorporated an inducible caspase-9 safety switch. ([jitc.bmj.com](https://jitc.bmj.com/content/13/5/e011533))

Other names

B7-H3 + CSPG4 co-targeting CAR-T cellsB7-H3 and CSPG4 co-targeting CAR-T cellsB-7-H3 and CSPG4 co-targeting CAR-T cellsB 7-H3 and CSPG4 co-targeting CAR-T cellsdual-specific B7-H3 and CSPG4 CAR-T cellsPan-CAR-T